Figure 1
Characterization of antitumor effects and E7-specific CD8+ T cell immune responses in TC-1 tumor-bearing mice treated with DMXAA. 5-8 weeks old C57BL/6 mice (5 per group) were challenged with 1 × 105 TC-1 cells subcutaneously. Mice were treated with a single dose of DMXAA given at day 13 after tumor challenge via i.p. injection. Tumor volume was monitored with calipers twice a week. One week after DMXAA treatment, splenocytes from tumor-bearing mice were harvested and characterized for E7-specific CD8+ T cells using intracellular IFN-γ staining followed by flow cytometry analysis. A) Line graph depicting the tumor volume in TC-1 tumor bearing mice treated with or without DMXAA (mean+ s.e.) B) Representative data of intracellular cytokine staining followed by flow cytometry analysis showing the number of E7-specific IFNγ+ CD8+ T cells in after DMXAA treatment. The data shown here are from one representative experiment of two performed.